FDA lifts hold on an Intellia CRISPR drug trial
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.
⚠️ 风险分析 中
摘要：FDA解除Intellia CRISPR药物试验暂停，但需加强安全措施。
影响：试验暂停解除可能恢复研发进程，但参与者死亡事件凸显临床试验安全风险，需加强监管合规以避免未来暂停或法律纠纷。
建议：加强临床试验安全监控，确保符合FDA法规，并评估知识产权保护策略。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.